# Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

> **NCT00244712** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 688 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** emtricitabine/tenofovir
- **DRUG:** abacavir/lamivudine

## Key facts

- **NCT ID:** NCT00244712
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 688 (ACTUAL)
- **Last updated:** 2010-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244712, "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00244712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*